Literature DB >> 18596905

Molecular pathogenesis of pulmonary arterial hypertension.

Marlene Rabinovitch1.   

Abstract

Recent investigations have suggested that it might be possible to reverse the pathology of pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal despite current treatments including i.v. prostacyclin. This review will address the cellular and molecular processes implicated in clinical, genetic, and experimental studies as underlying the pulmonary vascular abnormalities associated with PAH. Emerging treatments are aimed at inducing apoptosis of abnormal vascular cells that obstruct blood flow and at promoting regeneration of "lost" distal vasculature.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18596905      PMCID： PMC2439479          DOI： 10.1172/JCI33452

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  124 in total

1.  Expression of human herpesvirus 8 in primary pulmonary hypertension.

Authors:  Carlyne D Cool; Pradeep R Rai; Michael E Yeager; Daniel Hernandez-Saavedra; Amanda E Serls; Todd M Bull; Mark W Geraci; Kevin K Brown; John M Routes; Rubin M Tuder; Norbert F Voelkel
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

3.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension.

Authors:  A Chaouat; F Coulet; C Favre; G Simonneau; E Weitzenblum; F Soubrier; M Humbert
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

4.  Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes.

Authors:  Danielle B Ulanet; Nicholas A Flavahan; Livia Casciola-Rosen; Antony Rosen
Journal:  Arthritis Rheum       Date:  2004-01

5.  Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

Authors:  Toshihiko Nishimura; Laszlo T Vaszar; John L Faul; Guohua Zhao; Gerald J Berry; Lingfang Shi; Daoming Qiu; Gail Benson; Ronald G Pearl; Peter N Kao
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

6.  Sitaxsentan therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; David Langleben; Adaani Frost; Evelyn M Horn; Ronald Oudiz; Shelley Shapiro; Vallerie McLaughlin; Nicholas Hill; Victor F Tapson; Ivan M Robbins; Diane Zwicke; Benjamin Duncan; Richard A F Dixon; Lyn R Frumkin
Journal:  Am J Respir Crit Care Med       Date:  2003-11-20       Impact factor: 21.405

7.  Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells.

Authors:  Shen Zhang; Ivana Fantozzi; Donna D Tigno; Eunhee S Yi; Oleksandr Platoshyn; Patricia A Thistlethwaite; Jolene M Kriett; Gordon Yung; Lewis J Rubin; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-09       Impact factor: 5.464

8.  Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.

Authors:  Neil J Davie; Joseph T Crossno; Maria G Frid; Stephen E Hofmeister; John T Reeves; Dallas M Hyde; Todd C Carpenter; Jacqueline A Brunetti; Ian K McNiece; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-16       Impact factor: 5.464

9.  Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Saadia Eddahibi; Ari Chaouat; Nicholas Morrell; Elie Fadel; Claire Fuhrman; Anne-Sophie Bugnet; Philippe Dartevelle; Bruno Housset; Michel Hamon; E Weitzenblum; Serge Adnot
Journal:  Circulation       Date:  2003-10-06       Impact factor: 29.690

10.  S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.

Authors:  Steven Greenway; Robert Jan van Suylen; Gideon Du Marchie Sarvaas; Edwin Kwan; Noona Ambartsumian; Eugene Lukanidin; Marlene Rabinovitch
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307
View more
  153 in total

1.  Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing.

Authors:  Douglas L Prisco; Anthony L Sica; Arunabh Talwar; Mangala Narasimhan; Kennedy Omonuwa; Babak Hakimisefat; Sophy Dedopoulos; Nawid Shakir; Harly Greenberg
Journal:  Sleep Breath       Date:  2010-10-07       Impact factor: 2.816

Review 2.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 3.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

Review 4.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

5.  Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats.

Authors:  Aikaterini J Megalou; Chryssoula Glava; Dimitrios L Oikonomidis; Agapi Vilaeti; Maria G Agelaki; Giannis G Baltogiannis; Apostolos Papalois; Antonios P Vlahos; Theofilos M Kolettis
Journal:  Int J Clin Exp Med       Date:  2010-10-23

Review 6.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

7.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

8.  Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.

Authors:  Justine I Blum; Kaiser M Bijli; Tamara C Murphy; Jennifer M Kleinhenz; C Michael Hart
Journal:  Am J Med Sci       Date:  2016-04-04       Impact factor: 2.378

9.  Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.

Authors:  Shinji Arita; Noboru Arita; Yoshiaki Hikasa
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

10.  Recapitulation of developing artery muscularization in pulmonary hypertension.

Authors:  Abdul Q Sheikh; Janet K Lighthouse; Daniel M Greif
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.